Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in AustriaArchived
This paper describes the epidemiology of rotavirus (RV) in Austrian children before and during universal mass campaign.
European Parliament resolution on the evaluation of the management of H1N1 influenza in 2009-2010 in the EUArchived
The European Parliament adopted a resolution on the evaluation of the pandemic in its sitting on the 8th March 2011.
An Inactivated Cell-Culture Vaccine against Yellow FeverArchived
A double-blind, placebo-controlled, dose-escalation, phase 1 study was performed in 60 healthy subjects between 18 and 49 years of age. The two-dose regimen induced the development of neutralizing antibodies in high percentages of the subjects (from 88% to 100% of subjects depending on antigen content)”.
Global Action Plan to increase supply of pandemic influenza vaccines (GAP-II)Archived
The objective of WHO’s Global Influenza Vaccine Action Plan (which began in 2006) is to increase the use and supply of influenza vaccines on a routine basis.
Case inventory study from Sweden concerning association of Pandemrix vaccination and reports of narcolepsy with cataplexy in children and adolescentsArchived
ECDC has previously summarised information concerning the appearance of narcolepsy following the use of a specific pandemic vaccine (Pandemrix®) in children and adolescents in three European Countries.
No association found between pandemic influenza vaccination and Guillain-Barre Syndrome in EuropeArchived
Due to an association that was observed in the United States between a swine-flu based human influenza vaccine developed in 1976 and the disease acute polyneuropathy Guillain-Barré syndrome (GBS) (1,2), GBS was one of the adverse events that was monitored in Europe and North America (3) following the 2009 influenza pandemic vaccination campaigns.
Hepatitis A Seroprevalence in a population of immigrants at a French vaccination centreArchived
The authors retrospectively analyzed hepatitis A virus (HAV) seroprevalence in travellers who had been born and lived at least 1 year in a developing country, wanted to travel to a hepatitis A endemic area, and consulted at the vaccination centre of the Institut Pasteur of Paris between September 1, 2008 and February 28, 2010. HAV seroprevalence was 82.4 % for a population of 646 immigrants for whom data were available
Recommendation by the European Medicines Agency concerning Pandemrix vaccination and reports of narcolepsy in children and adolescentsArchived
EMA recommends restricting use in persons under 20 years of age Pandemrix to be used only in the absence of seasonal trivalent influenza vaccines, following link to very rare cases of narcolepsy in young people. Overall benefit-risk remains positive.